Healthcare & Life Sciences

Eilean Therapeutics

aliveseries-a
series-a
Stage
1
Investors

About

Eilean Therapeutics develops small molecule oncology therapies targeting major drivers of cancer resistance in hematologic malignancies, including pan-variant and mutation-specific inhibitors advancing towards clinical development.

Explore Eilean Therapeutics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.